Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 32 peer-reviewed journal articles Updated
Pulmonology · Mycobacterium avium complex pulmonary disease

What Follow-Up Is Needed After Pulmonary MAC Treatment?

At a Glance

After pulmonary MAC treatment, follow-up is individualized rather than automatic. Ongoing airway clearance and lung care, periodic sputum cultures or breathing tests, and prompt review of new symptoms help detect recurrence, reinfection, or another lung problem.

In this answer

4 sections

01

Managing Your Underlying Lung Health

02

Monitoring for Recurrence vs. Reinfection

03

Follow-up Appointments and Testing

04

When to Call Your Doctor

Completing your prolonged, multi-drug antibiotic treatment for pulmonary Mycobacterium avium complex (MAC) is a major milestone, but it does not mean your medical care is over. Even when active MAC is no longer detected—a milestone called culture conversion, where your sputum samples consistently test negative—the underlying lung conditions that made you susceptible remain. Because of underlying conditions like bronchiectasis, you will generally need long-term, individualized follow-up [1]. Your post-treatment plan should focus on managing your underlying lung health, maintaining airway clearance, and monitoring for signs of recurrence or a new infection [2][3].

Managing Your Underlying Lung Health

Even when cultures remain negative, structural changes in your lungs, like bronchiectasis (widened, scarred airways that trap mucus), require ongoing attention [4].

  • Airway Clearance: Continuing regular airway clearance techniques is commonly recommended, though the specific method and frequency should be tailored to you by a respiratory therapist or clinician [5]. Whether you use positive-expiratory-pressure devices or manual chest physiotherapy, clearing mucus helps prevent future infections [6]. Inhaling prescribed hypertonic saline can help thin mucus, but it can cause wheezing or bronchospasm in some people and should only be used as directed [7]. Safety note: Always clean and dry nebulizers and humidifiers thoroughly, as contaminated water in these devices can introduce new bacteria into your lungs [8].
  • Exercise and Pulmonary Rehabilitation: Staying active helps your lungs function better. Pulmonary rehabilitation and regular aerobic exercise can improve your stamina, airflow, and quality of life while you are stable [9][10].
  • Nutrition: Maintaining a healthy weight is important. In people with bronchiectasis, a lower body mass index (BMI) is linked to worse lung function and more frequent symptom flare-ups [11][12]. Unexplained weight loss can also be a warning sign of returning MAC or disease progression [4]. If you struggle to maintain your weight, your team may recommend a dietitian.
  • Infection Prevention: Protecting your lungs from other infections is an ongoing strategy. This includes staying up to date with seasonal influenza and pneumococcal vaccines, as well as discussing COVID-19 or RSV vaccines with your team [13][14]. MAC is widely found in the environment, including in soil and water. While you cannot eliminate your exposure entirely, you can discuss reasonable precautions with your doctor, such as avoiding poorly maintained hot tubs and ensuring proper ventilation [8].

Monitoring for Recurrence vs. Reinfection

It is common for MAC to return after successful treatment. When MAC comes back, it can be a relapse (the original bacteria surviving and multiplying again) or a reinfection (catching a new, different strain of MAC from the environment) [15][16].

Timing alone cannot tell these apart [15]. If you test positive for MAC again, specialized genetic testing (molecular typing) can sometimes compare the new bacteria to your original strain to determine which type of recurrence it is [17][18]. While not routinely necessary for every patient, this distinction can be useful because relapse can be associated with the bacteria developing resistance to the antibiotics you used before, which may influence future treatment decisions [15][19].

Keep in mind that finding MAC in your sputum does not always mean you need immediate treatment. Sometimes the bacteria are present in your airways without actively causing damage—a state known as colonization.

Follow-up Appointments and Testing

There is no single, universal schedule for post-treatment testing [20][21]. Your doctor will tailor a follow-up plan based on your risk factors, your symptoms, and local guidelines.

  • Sputum Cultures: Many specialists will arrange periodic, scheduled sputum testing for the first year or two after treatment, even if you feel well [1]. You will also need new cultures if your symptoms flare up [2]. While a formal diagnosis of recurring MAC often looks for two separate positive sputum cultures [22], do not wait for a second positive result to contact your team. A single unexpected positive culture should prompt clinical review [23]. If possible, always collect a sputum sample before starting any new antibiotics for a flare-up.
  • Imaging: CT scans involve radiation, so your doctor will order them based on clinical need rather than a strict routine [24]. It is normal for some structural abnormalities (like nodules or cavities) to persist even when you are cured [25]. If imaging worsens but MAC cultures are negative, your doctor will look for other issues like different bacterial infections (such as Pseudomonas or Nocardia), fungal diseases, or inflammatory problems [26][27].
  • Pulmonary Function Tests (PFTs): These breathing tests track airflow and other measures of lung function over time, which is especially helpful if your bronchiectasis is progressing [28].

When to Call Your Doctor

Recognizing a return of MAC can be tricky because the symptoms often look exactly like a regular bronchiectasis exacerbation (flare-up) [29][30]. Contact your pulmonologist or infectious disease specialist if you experience a change from your normal baseline, such as:

  • Increased cough or changes in mucus production
  • New shortness of breath or fatigue
  • Unexplained weight loss
  • Fevers or night sweats [31]

Emergency Warning: Hemoptysis (coughing up blood) can occur with bronchiectasis [31]. However, if you experience more than a small streak of blood, increasing bleeding, severe breathlessness, chest pain, dizziness, or confusion, seek emergency medical care immediately.

Do not assume a return of symptoms means you automatically need to restart your multi-drug MAC treatment. Your doctor must evaluate whether the symptoms are a MAC recurrence, a different infection, or a non-infectious flare-up of your underlying bronchiectasis before formulating a plan [26][32].

Common questions in this guide

How often should I have follow-up after finishing pulmonary MAC treatment?
There is no single follow-up schedule for everyone. Many specialists arrange periodic sputum cultures during the first year or two, while the timing depends on your symptoms, bronchiectasis, recurrence risk, and local guidance. Your clinician may also use lung function tests or imaging when clinically needed.
What tests check whether pulmonary MAC has returned?
Sputum cultures are the main test used to look for MAC after treatment. If symptoms or results raise concern, your clinician may also order breathing tests or a CT scan. A single positive culture needs medical review but does not always mean that treatment must restart.
Can pulmonary MAC come back after treatment?
Yes. MAC can return because the original bacteria survived, called a relapse, or because you acquired a different strain from the environment, called reinfection. Timing alone cannot reliably distinguish these causes, but specialized testing may compare the strains when MAC is found again.
What should I do to protect my lungs after MAC treatment?
Continue the airway-clearance routine recommended for you, and ask whether exercise or pulmonary rehabilitation would be appropriate. Maintaining a healthy weight, keeping recommended vaccines up to date, and cleaning nebulizers and humidifiers properly can also support lung health and reduce infection risks.
Which symptoms should make me call my doctor after MAC treatment?
Contact your pulmonologist or infectious disease specialist for a change from your usual baseline, such as more coughing, different mucus, new breathlessness, fatigue, unexplained weight loss, fever, or night sweats. More than a small streak of blood, increasing bleeding, severe breathlessness, chest pain, dizziness, or confusion requires emergency medical care.
Do abnormal CT findings mean that pulmonary MAC treatment failed?
Not necessarily. Nodules, cavities, and other structural lung changes can persist even when cultures are negative and treatment has worked. If imaging worsens, your clinician may investigate other infections or inflammatory problems rather than assuming MAC has returned.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the severity of my underlying bronchiectasis, what follow-up schedule and specific tests do you recommend for my first year off MAC antibiotics?
  2. 2.What specific airway clearance routine do you recommend I maintain long-term to help prevent future infections?
  3. 3.If my cough or mucus production increases, at what point should I bring in a sputum sample for testing rather than waiting it out?
  4. 4.Should I be referred to a pulmonary rehabilitation program to help rebuild my lung strength and stamina?
  5. 5.Are there any specific environmental precautions—such as with hot tubs, gardening, or humidifiers—I should adopt to minimize my risk of catching a new strain of MAC?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Pulmonary MAC Cause Lasting Lung Damage or Shorten Life?Can Gardening Expose You to Mycobacterium avium Complex?Can You Have Pulmonary MAC With a Negative AFB Smear?Does an AFB-Positive Sputum Test Mean I Have Tuberculosis?Does a Positive MAC Sputum Culture Always Mean Lung Disease?How Do Doctors Tell if Pulmonary MAC Treatment Is Working?Why Isn't Pulmonary MAC Contagious to Your Family?How Often Are CT Scans and Breathing Tests Used for MAC?How Quickly Does Untreated Pulmonary MAC Disease Progress?How Should I Collect Sputum for Pulmonary MAC Diagnosis?Is MAC After Culture Conversion a Relapse or Reinfection?Should I Get Immune or Lung Testing for Pulmonary MAC?What Do CT Scan Findings Mean in Pulmonary MAC Disease?What Factors Affect Your Chances of Clearing Pulmonary MAC?What Tests Check for Disseminated MAC Outside the Lungs?What Tests Diagnose Pulmonary MAC If I Can't Produce Sputum?What Water Precautions Are Recommended for MAC Lung Disease?When Is Watchful Waiting Appropriate for Pulmonary MAC?Why Do MAC Species ID and Macrolide Testing Matter?

References

References (32)
  1. 1

    Management of nontuberculous mycobacterial pulmonary disease.

    Adelman MH, Addrizzo-Harris DJ

    Current opinion in pulmonary medicine 2018; (24(3)):212-219 doi:10.1097/MCP.0000000000000473.

    PMID: 29470253
  2. 2

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  3. 3

    Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.

    Moon SM, Jhun BW, Baek SY, et al.

    Respiratory medicine 2019; (151()):1-7 doi:10.1016/j.rmed.2019.03.014.

    PMID: 31047103
  4. 4

    Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis.

    Faverio P, Stainer A, Bonaiti G, et al.

    International journal of molecular sciences 2016; (17(11)).

    PMID: 27854334
  5. 5

    Effectiveness of chest physiotherapy and pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: a narrative review.

    Annoni S, Bellofiore A, Repossini E, et al.

    Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2020; (90(1)) doi:10.4081/monaldi.2020.1107.

    PMID: 32072797
  6. 6

    Mucociliary clearance techniques for treating non-cystic fibrosis bronchiectasis: Is there evidence?

    Snijders D, Fernandez Dominguez B, Calgaro S, et al.

    International journal of immunopathology and pharmacology 2015; (28(2)):150-9 doi:10.1177/0394632015584724.

    PMID: 26078380
  7. 7

    Patient-managed interventions for adults with bronchiectasis: evidence, challenges and prospects.

    Spinou A, Lee AL, O'Neil B, et al.

    European respiratory review : an official journal of the European Respiratory Society 2024; (33(174)) doi:10.1183/16000617.0087-2024.

    PMID: 39477356
  8. 8

    Therapeutic Management of Bronchiectasis in Children and Adolescents: A Concise Narrative Review.

    Faverio P, Franco G, Landoni V, et al.

    Journal of clinical medicine 2024; (13(16)) doi:10.3390/jcm13164757.

    PMID: 39200899
  9. 9

    Practical approach to establishing pulmonary rehabilitation for people with non-COPD diagnoses.

    Granger CL, Morris NR, Holland AE

    Respirology (Carlton, Vic.) 2019; (24(9)):879-888 doi:10.1111/resp.13562.

    PMID: 31004384
  10. 10

    Exercise training for bronchiectasis.

    Lee AL, Gordon CS, Osadnik CR

    The Cochrane database of systematic reviews 2021; (4()):CD013110 doi:10.1002/14651858.CD013110.pub2.

    PMID: 33822364
  11. 11

    Association of body mass index with disease severity and prognosis in patients with non-cystic fibrosis bronchiectasis.

    Qi Q, Li T, Li JC, Li Y

    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica 2015; (48(8)):715-24.

    PMID: 26176309
  12. 12

    Addressing treatable traits in bronchiectasis through non-pharmacological therapies: a narrative review.

    Lee AL, Spinou A, Basavaraj A

    Journal of thoracic disease 2025; (17(6)):4302-4322 doi:10.21037/jtd-2024-2106.

    PMID: 40688306
  13. 13

    Bronchiectasis in rheumatoid arthritis. A clinical appraisial.

    Duarte AC, Porter J, Leandro MJ

    Joint bone spine 2020; (87(5)):419-424 doi:10.1016/j.jbspin.2019.12.006.

    PMID: 32007647
  14. 14

    Nontuberculous mycobacteria in cystic fibrosis and non-cystic fibrosis bronchiectasis.

    Park IK, Olivier KN

    Seminars in respiratory and critical care medicine 2015; (36(2)):217-24 doi:10.1055/s-0035-1546751.

    PMID: 25826589
  15. 15

    Relapse versus Reinfection of Mycobacterium avium Complex Pulmonary Disease. Patient Characteristics and Macrolide Susceptibility.

    Boyle DP, Zembower TR, Qi C

    Annals of the American Thoracic Society 2016; (13(11)):1956-1961 doi:10.1513/AnnalsATS.201605-344BC.

    PMID: 27599038
  16. 16

    Understanding recurrence in Mycobacterium avium complex pulmonary disease: genotypic strategies to support clinical decision-making.

    Trinh MP, Shin SJ, Shin M-K

    Journal of clinical microbiology 2026; (64(3)):e0108625 doi:10.1128/jcm.01086-25.

    PMID: 41190925
  17. 17

    Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease.

    Jhun BW, Moon SM, Kim SY, et al.

    Antimicrobial agents and chemotherapy 2018; (62(2)) doi:10.1128/AAC.01812-17.

    PMID: 29203483
  18. 18

    Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype.

    Koh WJ, Moon SM, Kim SY, et al.

    The European respiratory journal 2017; (50(3)) doi:10.1183/13993003.02503-2016.

    PMID: 28954780
  19. 19

    Monotherapy: Key cause of macrolide-resistant Mycobacterium avium complex disease.

    Loewenstein D, van Balveren L, Lemson A, et al.

    Respiratory medicine 2023; (217()):107366 doi:10.1016/j.rmed.2023.107366.

    PMID: 37481170
  20. 20

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  21. 21

    Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases.

    Lange C, Böttger EC, Cambau E, et al.

    The Lancet. Infectious diseases 2022; (22(7)):e178-e190 doi:10.1016/S1473-3099(21)00586-7.

    PMID: 35090639
  22. 22

    Combination of anti-glycopeptidolipid-core IgA antibody and clinical features for diagnosing potential nontuberculous mycobacterium pulmonary disease in routine practice.

    Iwasaki T, Yamaguchi F, Hayashi M, et al.

    Therapeutic advances in respiratory disease 2022; (16()):17534666221138002 doi:10.1177/17534666221138002.

    PMID: 36444981
  23. 23

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  24. 24

    Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation.

    Urabe N, Sakamoto S, Tokita N, et al.

    BMC pulmonary medicine 2024; (24(1)):442 doi:10.1186/s12890-024-03261-w.

    PMID: 39256717
  25. 25

    Impact of chronic co-infection in pulmonary Mycobacterium avium complex disease after treatment initiation.

    Urabe N, Sakamoto S, Shimanuki Y, et al.

    BMC pulmonary medicine 2022; (22(1)):157 doi:10.1186/s12890-022-01947-7.

    PMID: 35468795
  26. 26

    Pulmonary nocardiosis following nodular bronchiectatic Mycobacterium avium complex pulmonary disease in an immunocompetent patient.

    Ito Y, Miwa S, Shirai M

    BMJ case reports 2023; (16(11)) doi:10.1136/bcr-2023-256007.

    PMID: 37973540
  27. 27

    Duration of antibiotic therapy in non-cystic fibrosis bronchiectasis.

    Somayaji R, Goss CH

    Current pulmonology reports 2019; (8(4)):160-165 doi:10.1007/s13665-019-00235-w.

    PMID: 31875166
  28. 28

    Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary disease.

    Kimizuka Y, Hoshino Y, Nishimura T, et al.

    PloS one 2019; (14(4)):e0216034 doi:10.1371/journal.pone.0216034.

    PMID: 31022253
  29. 29

    Characteristics of patients with bronchoscopy-diagnosed pulmonary Mycobacterium avium complex infection.

    Urabe N, Sakamoto S, Sano G, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2018; (24(10)):822-827 doi:10.1016/j.jiac.2018.06.014.

    PMID: 30054229
  30. 30

    Clinical relevance of pulmonary non-tuberculous mycobacterial isolates in three reference centres in Belgium: a multicentre retrospective analysis.

    Vande Weygaerde Y, Cardinaels N, Bomans P, et al.

    BMC infectious diseases 2019; (19(1)):1061 doi:10.1186/s12879-019-4683-y.

    PMID: 31847834
  31. 31

    MAC Attack: Clinical Correlates of Mycobacterium avium Complex Infection Among Patients With and Without Cancer.

    Gupta K, Feinstein MB, Goldman DA, et al.

    Journal of clinical medicine research 2020; (12(3)):142-149 doi:10.14740/jocmr4058.

    PMID: 32231749
  32. 32

    Non-Cystic Fibrosis Bronchiectasis in Adults: A Review.

    Barker AF, Karamooz E

    JAMA 2025; (334(3)):253-264 doi:10.1001/jama.2025.2680.

    PMID: 40293759

This page provides general information about follow-up after pulmonary MAC treatment and is not medical advice. Your pulmonologist or infectious disease specialist should tailor testing and care to your symptoms and underlying lung health.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.